Back to News
Market Impact: 0.15
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
Source: GlobeNewswire
Healthcare & Biotech
Agomab said open-label extension (OLE) data from its Phase 2a STENOVA study will be presented in an oral session at United European Gastroenterology (UEG) Week 2026. The announcement provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
AGMB0.30
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- William Blair downgrades Alignment Healthcare stock rating on cost pressures
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search
- Automating Financial Model Updates: A Source-Controlled Workflow